{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:07:04Z","timestamp":1762358824736,"version":"build-2065373602"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00105-025-05605-x","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:49:40Z","timestamp":1761212980000},"page":"735-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prim\u00e4r kutane B-Zell-Lymphome\u00a0\u2013 ein \u00dcberblick \u00fcber Bekanntes und Neues","Primary cutaneous B-cell lymphomas\u2014an\u00a0overview of established and novel aspects"],"prefix":"10.1007","volume":"76","author":[{"given":"Inga","family":"Hansen-Abeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Booken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"5605_CR1","doi-asserted-by":"crossref","unstructured":"Dumont M, Battistella M, Ram-Wolff C, Bagot M, de Masson A (2020) Diagnosis and treatment of primary cutaneous B\u2011cell lymphomas: state of the art and perspectives. Cancers 12(6)","DOI":"10.3390\/cancers12061497"},{"issue":"4","key":"5605_CR2","first-page":"537","volume":"20","author":"E Dippel","year":"2022","unstructured":"Dippel\u00a0E, Assaf\u00a0C, Becker\u00a0JC, von Bergwelt-Baildon\u00a0M, Bernreiter\u00a0S, Cozzio\u00a0A et\u00a0al (2022) S2k-Guidelines\u2014Cutaneous lymphomas (ICD\u00a010 C82\u2013C86): update 2021. J\u00a0Dtsch Dermatol Ges 20(4):537\u2013554","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"5605_CR3","first-page":"1207","volume":"14","author":"JP Nicolay","year":"2016","unstructured":"Nicolay\u00a0JP, Wobser\u00a0M (2016) Cutaneous B\u2011cell lymphomas\u2014pathogenesis, diagnostic workup, and therapy. J\u00a0Dtsch Dermatol Ges 14(12):1207\u20131224","journal-title":"J Dtsch Dermatol Ges"},{"key":"5605_CR4","doi-asserted-by":"crossref","unstructured":"Barbati ZR, Charli-Joseph Y (2025) Unveiling primary cutaneous B\u2011cell lymphomas: new insights into diagnosis and treatment strategies. Cancers 17(7)","DOI":"10.3390\/cancers17071202"},{"issue":"16","key":"5605_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze\u00a0R, Cerroni\u00a0L, Kempf\u00a0W, Berti\u00a0E, Facchetti\u00a0F, Swerdlow\u00a0SH et\u00a0al (2019) The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133(16):1703\u20131714","journal-title":"Blood"},{"issue":"3","key":"5605_CR6","first-page":"205","volume":"158","author":"M Blanchard","year":"2023","unstructured":"Blanchard\u00a0M, Hoetzenecker\u00a0W, Blanchard\u00a0G, Guenova\u00a0E (2023) What is new about primary cutaneous B\u00a0cell lymphomas. Ital J Dermatol Venerol 158(3):205\u2013216","journal-title":"Ital J Dermatol Venerol"},{"issue":"11","key":"5605_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo\u00a0E, Jaffe\u00a0ES, Cook\u00a0JR, Quintanilla-Martinez\u00a0L, Swerdlow\u00a0SH, Anderson\u00a0KC et\u00a0al (2022) The International Consensus Classification of Mature Lymphoid Neoplasms: a\u00a0report from the Clinical Advisory Committee. Blood 140(11):1229\u20131253","journal-title":"Blood"},{"issue":"2","key":"5605_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"YH Kim","year":"2007","unstructured":"Kim\u00a0YH, Willemze\u00a0R, Pimpinelli\u00a0N, Whittaker\u00a0S, Olsen\u00a0EA, Ranki\u00a0A et\u00a0al (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a\u00a0proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(2):479\u2013484","journal-title":"Blood"},{"issue":"7","key":"5605_CR9","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I, Attygalle\u00a0AD, Araujo\u00a0IBO, Berti\u00a0E et\u00a0al (2022) The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"9","key":"5605_CR10","first-page":"1254","volume":"22","author":"S Melchers","year":"2024","unstructured":"Melchers\u00a0S, Albrecht\u00a0JD, Kempf\u00a0W, Nicolay\u00a0JP (2024) The fifth edition of the WHO-Classification\u2014what is new for cutaneous lymphomas? J\u00a0Dtsch Dermatol Ges 22(9):1254\u20131265","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"5605_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","volume":"69","author":"O Servitje","year":"2013","unstructured":"Servitje\u00a0O, Muniesa\u00a0C, Benavente\u00a0Y, Monsalvez\u00a0V, Garcia-Muret\u00a0MP, Gallardo\u00a0F et\u00a0al (2013) Primary cutaneous marginal zone B\u2011cell lymphoma: response to treatment and disease-free survival in a\u00a0series of 137 patients. J\u00a0Am Acad Dermatol 69(3):357\u2013365","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl\u00a02","key":"5605_CR12","first-page":"9723","volume":"16","author":"C Ciolfi","year":"2024","unstructured":"Ciolfi\u00a0C, Tartaglia\u00a0J, Sernicola\u00a0A, Alaibac\u00a0M (2024) Clinician\u2019s perspective on the diagnosis of primary cutaneous B\u2011cell lymphoma. Dermatol Reports 16(Suppl\u00a02):9723","journal-title":"Dermatol Reports"},{"issue":"4","key":"5605_CR13","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/j.clml.2021.10.009","volume":"22","author":"DO Leary","year":"2022","unstructured":"Leary\u00a0DO, Goyal\u00a0N, Rubin\u00a0N, Goyal\u00a0A (2022) Characterization of primary and secondary cutaneous B\u2011cell lymphomas: a\u00a0population-based study of 4758 patients. Clin Lymphoma Myeloma Leuk 22(4):e269\u2013e278","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5605_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00105-017-4022-4","volume":"68","author":"M Wobser","year":"2017","unstructured":"Wobser\u00a0M (2017) Treatment of indolent cutaneous B\u2011cell lymphoma. Hautarzt 68(9):721\u2013726","journal-title":"Hautarzt"},{"issue":"10","key":"5605_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/PAS.0000000000001363","volume":"43","author":"ED Carlsen","year":"2019","unstructured":"Carlsen\u00a0ED, Swerdlow\u00a0SH, Cook\u00a0JR, Gibson\u00a0SE (2019) Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases. Am J Surg Pathol 43(10):1403\u20131412","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"5605_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.15183","volume":"177","author":"M Wobser","year":"2017","unstructured":"Wobser\u00a0M, Maurus\u00a0K, Roth\u00a0S, Appenzeller\u00a0S, Weyandt\u00a0G, Goebeler\u00a0M et\u00a0al (2017) Myeloid differentiation primary response 88 mutations in a\u00a0distinct type of cutaneous marginal-zone lymphoma with a\u00a0nonclass-switched immunoglobulin\u00a0M immunophenotype. Br J Dermatol 177(2):564\u2013566","journal-title":"Br J Dermatol"},{"key":"5605_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351346","author":"R Willemze","year":"2025","unstructured":"Willemze\u00a0R, Assaf\u00a0C, Bagot\u00a0M, Beylot-Barry\u00a0M, Berti\u00a0E, Busschots\u00a0AM et\u00a0al (2025) EORTC\/USCLC\/ISCL consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. Br J Dermatol. https:\/\/doi.org\/10.1182\/blood-2011-05-351346","journal-title":"Br J Dermatol"},{"issue":"6","key":"5605_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/bjd.19644","volume":"184","author":"G Dobos","year":"2021","unstructured":"Dobos\u00a0G, de Masson\u00a0A, Ram-Wolff\u00a0C, Beylot-Barry\u00a0M, Pham-Ledard\u00a0A, Ortonne\u00a0N et\u00a0al (2021) Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol 184(6):1059\u20131067","journal-title":"Br J Dermatol"},{"issue":"4","key":"5605_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.1365-2133.2001.04128.x","volume":"144","author":"FJ Child","year":"2001","unstructured":"Child\u00a0FJ, Russell-Jones\u00a0R, Woolford\u00a0AJ, Calonje\u00a0E, Photiou\u00a0A, Orchard\u00a0G et\u00a0al (2001) Absence of the t(14;18) chromosomal translocation in primary cutaneous B\u2011cell lymphoma. Br J Dermatol 144(4):735\u2013744","journal-title":"Br J Dermatol"},{"issue":"3","key":"5605_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/bloodadvances.2020002469","volume":"5","author":"XA Zhou","year":"2021","unstructured":"Zhou\u00a0XA, Yang\u00a0J, Ringbloom\u00a0KG, Martinez-Escala\u00a0ME, Stevenson\u00a0KE, Wenzel\u00a0AT et\u00a0al (2021) Genomic landscape of cutaneous follicular lymphomas reveals 2\u00a0subgroups with clinically predictive molecular features. Blood Adv 5(3):649\u2013661","journal-title":"Blood Adv"},{"issue":"9","key":"5605_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00105-017-4018-0","volume":"68","author":"C Lamos","year":"2017","unstructured":"Lamos\u00a0C, Dippel\u00a0E (2017) Aggressive primary cutaneous B\u2011cell lymphomas and novel EBV+ entities. Hautarzt 68(9):727\u2013739","journal-title":"Hautarzt"},{"issue":"12","key":"5605_CR22","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1038\/s41379-020-0599-8","volume":"33","author":"T Ikeda","year":"2020","unstructured":"Ikeda\u00a0T, Gion\u00a0Y, Sakamoto\u00a0M, Tachibana\u00a0T, Nishikori\u00a0A, Nishimura\u00a0MF et\u00a0al (2020) Clinicopathological analysis of 34 Japanese patients with EBV-positive mucocutaneous ulcer. Mod Pathol 33(12):2437\u20132448","journal-title":"Mod Pathol"},{"key":"5605_CR23","doi-asserted-by":"crossref","unstructured":"Ikeda T, Gion Y, Nishimura Y, Nishimura MF, Yoshino T, Sato Y (2021) Epstein-Barr virus-positive mucocutaneous ulcer: a\u00a0unique and curious disease entity. Int J Mol Sci 22(3)","DOI":"10.3390\/ijms22031053"},{"key":"5605_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-016-0042-5","volume":"5","author":"TK Roberts","year":"2015","unstructured":"Roberts\u00a0TK, Chen\u00a0X, Liao\u00a0JJ (2015) Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a\u00a0case report and systematic review of the literature. Exp Hematol Oncol 5:13","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"5605_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jaad.2021.11.068","volume":"88","author":"JA Plaza","year":"2023","unstructured":"Plaza\u00a0JA, Gru\u00a0AA, Sangueza\u00a0OP, Lourenco\u00a0SV, Puccio\u00a0FB, Sanches\u00a0JA et\u00a0al (2023) An update on viral-induced cutaneous lymphoproliferative disorders. CME Part\u00a0I. J\u00a0Am Acad Dermatol 88(5):965\u2013980","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5605_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","volume":"140","author":"EA Olsen","year":"2022","unstructured":"Olsen\u00a0EA, Whittaker\u00a0S, Willemze\u00a0R, Pinter-Brown\u00a0L, Foss\u00a0F, Geskin\u00a0L et\u00a0al (2022) Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 140(5):419\u2013437","journal-title":"Blood"},{"key":"5605_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3389\/fonc.2020.01163","volume":"10","author":"CCV Lang","year":"2020","unstructured":"Lang\u00a0CCV, Ramelyte\u00a0E, Dummer\u00a0R (2020) Innovative therapeutic approaches in primary cutaneous B\u00a0cell lymphoma. Front Oncol 10:1163","journal-title":"Front Oncol"},{"key":"5605_CR28","doi-asserted-by":"publisher","first-page":"115064","DOI":"10.1016\/j.ejca.2024.115064","volume":"212","author":"K Elsayad","year":"2024","unstructured":"Elsayad\u00a0K, Guenova\u00a0E, Assaf\u00a0C, Nicolay\u00a0JP, Trautinger\u00a0F, Stadler\u00a0R et\u00a0al (2024) Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group. Eur J Cancer 212:115064","journal-title":"Eur J Cancer"},{"issue":"1","key":"5605_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","volume":"92","author":"L Specht","year":"2015","unstructured":"Specht\u00a0L, Dabaja\u00a0B, Illidge\u00a0T, Wilson\u00a0LD, Hoppe\u00a0RT, International Lymphoma Radiation Oncology\u00a0G (2015) Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology\u00a0Group. Int J Radiat Oncol Biol Phys 92(1):32\u201339","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"5605_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","volume":"24","author":"JR Goodlad","year":"2000","unstructured":"Goodlad\u00a0JR, Davidson\u00a0MM, Hollowood\u00a0K, Ling\u00a0C, MacKenzie\u00a0C, Christie\u00a0I et\u00a0al (2000) Primary cutaneous B\u2011cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 24(9):1279\u20131285","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"5605_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","volume":"28","author":"GS Wood","year":"2001","unstructured":"Wood\u00a0GS, Kamath\u00a0NV, Guitart\u00a0J, Heald\u00a0P, Kohler\u00a0S, Smoller\u00a0BR et\u00a0al (2001) Absence of Borrelia burgdorferi DNA in cutaneous B\u2011cell lymphomas from the United States. J\u00a0Cutan Pathol 28(10):502\u2013507","journal-title":"J Cutan Pathol"},{"issue":"2","key":"5605_CR32","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.clml.2018.10.003","volume":"19","author":"RB Sinit","year":"2019","unstructured":"Sinit\u00a0RB, Horan\u00a0KL, Dorer\u00a0RK, Aboulafia\u00a0DM (2019) Epstein-Barr virus-positive Mucocutaneous ulcer: case report and review of the first 100 published cases. Clin Lymphoma Myeloma Leuk 19(2):e81\u2013e92","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5605_CR33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/ijd.17564","volume":"64","author":"V Nikolaou","year":"2025","unstructured":"Nikolaou\u00a0V, Koumprentziotis\u00a0IA, Papadavid\u00a0E, Patsatsi\u00a0A, Diavati\u00a0S, Tsimpidakis\u00a0A et\u00a0al (2025) Clinical features, treatment options and outcomes in primary cutaneous B\u2011cell lymphomas: a\u00a0real-world, multicenter, retrospective study. Int J Dermatol 64(5):882\u2013889","journal-title":"Int J Dermatol"},{"issue":"12","key":"5605_CR34","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","volume":"25","author":"NJ Senff","year":"2007","unstructured":"Senff\u00a0NJ, Hoefnagel\u00a0JJ, Jansen\u00a0PM, Vermeer\u00a0MH, van Baarlen\u00a0J, Blokx\u00a0WA et\u00a0al (2007) Reclassification of 300 primary cutaneous B\u2011Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J\u00a0Clin Oncol 25(12):1581\u20131587","journal-title":"J Clin Oncol"},{"issue":"9","key":"5605_CR35","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","volume":"137","author":"S Mareschal","year":"2017","unstructured":"Mareschal\u00a0S, Pham-Ledard\u00a0A, Viailly\u00a0PJ, Dubois\u00a0S, Bertrand\u00a0P, Maingonnat\u00a0C et\u00a0al (2017) Identification of somatic mutations in primary cutaneous diffuse large B\u2011cell Lymphoma, leg type by massive parallel sequencing. J\u00a0Invest Dermatol 137(9):1984\u20131994","journal-title":"J Invest Dermatol"},{"issue":"10","key":"5605_CR36","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cam4.865","volume":"5","author":"M Lucioni","year":"2016","unstructured":"Lucioni\u00a0M, Berti\u00a0E, Arcaini\u00a0L, Croci\u00a0GA, Maffi\u00a0A, Klersy\u00a0C et\u00a0al (2016) Primary cutaneous B\u2011cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Med 5(10):2740\u20132755","journal-title":"Cancer Med"},{"issue":"11","key":"5605_CR37","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1097\/PAS.0000000000001132","volume":"42","author":"AMR Schrader","year":"2018","unstructured":"Schrader\u00a0AMR, Jansen\u00a0PM, Vermeer\u00a0MH, Kleiverda\u00a0JK, Vermaat\u00a0JSP, Willemze\u00a0R (2018) High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B\u2011cell lymphoma, leg type. Am J Surg Pathol 42(11):1488\u20131494","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"5605_CR38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jaad.2018.07.042","volume":"79","author":"A Goyal","year":"2018","unstructured":"Goyal\u00a0A, Goyal\u00a0K, Bohjanen\u00a0K (2018) Mortality in intravascular large B\u2011cell lymphoma: a\u00a0SEER analysis. J\u00a0Am Acad Dermatol 79(6):1163\u20131165","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"5605_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1287363","volume":"58","author":"DJ Rajyaguru","year":"2017","unstructured":"Rajyaguru\u00a0DJ, Bhaskar\u00a0C, Borgert\u00a0AJ, Smith\u00a0A, Parsons\u00a0B (2017) Intravascular large B\u2011cell lymphoma in the United States (US): a\u00a0population-based study using surveillance, epidemiology, and end results program and national cancer database. Leuk Lymphoma 58(9):1\u20139","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5605_CR40","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/curroncol29050237","volume":"29","author":"T Breakell","year":"2022","unstructured":"Breakell\u00a0T, Waibel\u00a0H, Schliep\u00a0S, Ferstl\u00a0B, Erdmann\u00a0M, Berking\u00a0C et\u00a0al (2022) Intravascular large B\u2011cell lymphoma: a\u00a0review with a\u00a0focus on the prognostic value of skin involvement. Curr Oncol 29(5):2909\u20132919","journal-title":"Curr Oncol"},{"issue":"18","key":"5605_CR41","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","volume":"131","author":"AMR Schrader","year":"2018","unstructured":"Schrader\u00a0AMR, Jansen\u00a0PM, Willemze\u00a0R, Vermeer\u00a0MH, Cleton-Jansen\u00a0AM, Somers\u00a0SF et\u00a0al (2018) High prevalence of MYD88 and CD79B mutations in intravascular large B\u2011cell lymphoma. Blood 131(18):2086\u20132089","journal-title":"Blood"},{"issue":"5","key":"5605_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/hon.2919","volume":"39","author":"RM Kraft","year":"2021","unstructured":"Kraft\u00a0RM, Ansell\u00a0SM, Villasboas\u00a0JC, Bennani\u00a0NN, Wang\u00a0Y, Habermann\u00a0TM et\u00a0al (2021) Outcomes in primary cutaneous diffuse large B\u2011cell lymphoma, leg type. Hematol Oncol 39(5):658\u2013663","journal-title":"Hematol Oncol"},{"issue":"5","key":"5605_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1159\/000522053","volume":"238","author":"M Zehnder","year":"2022","unstructured":"Zehnder\u00a0M, Amarov\u00a0B, Abrunhosa-Branquinho\u00a0AN, Maiwald-Urosevic\u00a0M, Muhleisen\u00a0B, Saulite\u00a0I et\u00a0al (2022) Radiotherapy as a\u00a0treatment option for local disease control in primary cutaneous diffuse large B\u2011cell lymphoma, leg type. Dermatology 238(5):967\u2013976","journal-title":"Dermatology"},{"issue":"4","key":"5605_CR44","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4081\/rt.2015.6067","volume":"7","author":"E Gupta","year":"2015","unstructured":"Gupta\u00a0E, Accurso\u00a0J, Sluzevich\u00a0J, Menke\u00a0DM, Tun\u00a0HW (2015) Excellent outcome of Immunomodulation or Bruton\u2019s Tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B\u2011cell lymphoma, leg type. Rare Tumors 7(4):6067","journal-title":"Rare Tumors"},{"issue":"5","key":"5605_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2008.12.045","volume":"61","author":"B Horvath","year":"2009","unstructured":"Horvath\u00a0B, Demeter\u00a0J, Eros\u00a0N, Harsing\u00a0J, Csomor\u00a0J, Matolcsy\u00a0A et\u00a0al (2009) Intravascular large B\u2011cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. J\u00a0Am Acad Dermatol 61(5):885\u2013888","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5605_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000228328","volume":"219","author":"R Feldmann","year":"2009","unstructured":"Feldmann\u00a0R, Schierl\u00a0M, Sittenthaler\u00a0M, Jahn\u00a0R, Wogritsch\u00a0C, Cerroni\u00a0L et\u00a0al (2009) Intravascular large B\u2011cell lymphoma of the skin: typical clinical manifestations and a\u00a0favourable response to rituximab-containing therapy. Dermatology 219(4):344\u2013346","journal-title":"Dermatology"},{"issue":"2","key":"5605_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","volume":"143","author":"AJ Ferreri","year":"2008","unstructured":"Ferreri\u00a0AJ, Dognini\u00a0GP, Bairey\u00a0O, Szomor\u00a0A, Montalban\u00a0C, Horvath\u00a0B et\u00a0al (2008) The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in \u2018Western\u2019 patients with intravascular large B\u2011cell lymphoma. Br J Haematol 143(2):253\u2013257","journal-title":"Br J Haematol"},{"issue":"4","key":"5605_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bmt.2016.339","volume":"52","author":"J Meissner","year":"2017","unstructured":"Meissner\u00a0J, Finel\u00a0H, Dietrich\u00a0S, Boumendil\u00a0A, Kanfer\u00a0E, Laboure\u00a0G et\u00a0al (2017) Autologous hematopoietic stem cell transplantation for intravascular large B\u2011cell lymphoma: the European Society for Blood and Marrow Transplantation experience. Bone Marrow Transplant 52(4):650\u2013652","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5605_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41409-019-0491-7","volume":"54","author":"K Kato","year":"2019","unstructured":"Kato\u00a0K, Mori\u00a0T, Kim\u00a0SW, Sawa\u00a0M, Sakai\u00a0T, Hashimoto\u00a0H et\u00a0al (2019) Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B\u2011cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 54(9):1515\u20131517","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5605_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","volume":"21","author":"K Shimada","year":"2020","unstructured":"Shimada\u00a0K, Yamaguchi\u00a0M, Atsuta\u00a0Y, Matsue\u00a0K, Sato\u00a0K, Kusumoto\u00a0S et\u00a0al (2020) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B\u2011cell lymphoma (PRIMEUR-IVL): a\u00a0multicentre, single-arm, phase\u00a02\u00a0trial. Lancet Oncol 21(4):593\u2013602","journal-title":"Lancet Oncol"},{"issue":"5","key":"5605_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","volume":"150","author":"F Grange","year":"2014","unstructured":"Grange\u00a0F, Joly\u00a0P, Barbe\u00a0C, Bagot\u00a0M, Dalle\u00a0S, Ingen-Housz-Oro\u00a0S et\u00a0al (2014) Improvement of survival in patients with primary cutaneous diffuse large B\u2011cell lymphoma, leg type, in France. JAMA Dermatol 150(5):535\u2013541","journal-title":"JAMA Dermatol"},{"issue":"9","key":"5605_CR52","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","volume":"143","author":"F Grange","year":"2007","unstructured":"Grange\u00a0F, Beylot-Barry\u00a0M, Courville\u00a0P, Maubec\u00a0E, Bagot\u00a0M, Vergier\u00a0B et\u00a0al (2007) Primary cutaneous diffuse large B\u2011cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60\u00a0cases. Arch Dermatol 143(9):1144\u20131150","journal-title":"Arch Dermatol"},{"issue":"2","key":"5605_CR53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2018.214122","volume":"105","author":"JS Vermaat","year":"2020","unstructured":"Vermaat\u00a0JS, Somers\u00a0SF, de Wreede\u00a0LC, Kraan\u00a0W, de Groen\u00a0RAL, Schrader\u00a0AMR et\u00a0al (2020) MYD88 mutations identify a\u00a0molecular subgroup of diffuse large B\u2011cell lymphoma with an unfavorable prognosis. Haematologica 105(2):424\u2013434","journal-title":"Haematologica"},{"issue":"5","key":"5605_CR54","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/jid.2008.357","volume":"129","author":"NJ Senff","year":"2009","unstructured":"Senff\u00a0NJ, Zoutman\u00a0WH, Vermeer\u00a0MH, Assaf\u00a0C, Berti\u00a0E, Cerroni\u00a0L et\u00a0al (2009) Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B\u2011cell lymphoma, leg type. J\u00a0Invest Dermatol 129(5):1149\u20131155","journal-title":"J Invest Dermatol"},{"issue":"3","key":"5605_CR55","first-page":"275","volume":"17","author":"M Felcht","year":"2019","unstructured":"Felcht\u00a0M, Klemke\u00a0CD, Nicolay\u00a0JP, Weiss\u00a0C, Assaf\u00a0C, Wobser\u00a0M et\u00a0al (2019) Primary cutaneous diffuse large B\u2011cell lymphoma, NOS and leg type: clinical, morphologic and prognostic differences. J\u00a0Dtsch Dermatol Ges 17(3):275\u2013285","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"5605_CR56","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ajh.26968","volume":"98","author":"AC Hristov","year":"2023","unstructured":"Hristov\u00a0AC, Tejasvi\u00a0T, Wilcox\u00a0RA (2023) Cutaneous B\u2011cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(8):1326\u20131332","journal-title":"Am J Hematol"},{"issue":"11","key":"5605_CR57","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","volume":"139","author":"O Ducharme","year":"2019","unstructured":"Ducharme\u00a0O, Beylot-Barry\u00a0M, Pham-Ledard\u00a0A, Bohers\u00a0E, Viailly\u00a0PJ, Bandres\u00a0T et\u00a0al (2019) Mutations of the B\u2011Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B\u2011Cell Lymphoma Leg Type. J\u00a0Invest Dermatol 139(11):2334\u20132342.e8","journal-title":"J Invest Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05605-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:03:13Z","timestamp":1762358593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05605-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5605"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05605-x","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"6 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"N.\u00a0Booken\n                      : A. Finanzielle Interessen: Referentin: Takeda, Recordati, Kyowa Kirin, Novartis; Reisekosten: Kyowa Kirin, Recordati, Takeda. - B. Nichtfinanzielle Interessen: Angestellt im Universit\u00e4tsklinikum Hamburg-Eppendorf seit 01\/2017 | Mitgliedschaften: Norddeutsche Dermatologische Gesellschaft, Deutsche Dermatologische Gesellschaft, Deutsche Krebsgesellschaft, Arbeitsgemeinschaft onkologische Dermatologie, Arbeitsgemeinschaft dermatologische Histologie.\n                      S.W.\u00a0Schneider\n                      : A. Finanzielle Interessen: Referent: Leo Pharma, GSK, AbbVie, Pfizer. - B. Nichtfinanzielle Interessen: Klinikdirektor, au\u00dfertariflich angestellt im Universit\u00e4tsklinikum Hamburg Eppendorf seit 10\/2016 | Mitgliedschaften: Norddeutsche Dermatologische Gesellschaft, Deutsche Dermatologische Gesellschaft, Dt. Physiologische Gesellschaft, Arbeitsgemeinschaft dermatologische Forschung.\n                      I.\u00a0Hansen-Abeck\n                      : A. Finanzielle Interessen: Referentin: Sanofi, BMS, Takeda, Reisekosten: Kyowa Kirin, Almirall. - B. Nichtfinanzielle Interessen: Angestellt im Universit\u00e4tsklinikum Hamburg-Eppendorf seit 07\/2021 | Mitgliedschaften: Norddeutsche Dermatologische Gesellschaft, Deutsche Dermatologische Gesellschaft, Deutsche Gesellschaft f\u00fcr Dermatochirurgie.\n                      A.\u00a0Menz\n                      : A. Finanzielle Interessen: A.\u00a0Menz gibt an, dass kein finanzieller Interessenkonflikt besteht. - B. Nichtfinanzielle Interessen: Angestellt im Universit\u00e4tsklinikum Hamburg-Eppendorf seit 08\/1998, Ober\u00e4rztin, Institut f\u00fcr Pathologie | Mitgliedschaften: Arbeitsgemeinschaft dermatologische Histologie, American Society for Dermatopathology, Internationale Akademie f\u00fcr Pathologie, European Academy of Dermatology and Venerology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}